Results 11 to 20 of about 60,909 (346)
Transthyretin cardiac amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and ...
A. Porcari, M. Fontana, J. Gillmore
semanticscholar +5 more sources
Evolution of Transthyretin in Marsupials [PDF]
The evolution of the expression and the structure of the gene for transthyretin, a thyroxine‐binding plasma protein formerly called prealbumin, was studied in three marsupial species: the South American polyprotodont Monodelphis domestica, the Australian polyprotodont Sminthopsis macroura and the Australian diprotodont Petaurus breviceps.
Wei Duan +11 more
openalex +6 more sources
BACKGROUND: Transthyretin protein experiences misfolding and aggregation in preeclampsia due to placental ischemia and inflammation. Placental endothelial damage occurring in preeclampsia stimulates the production of larger young platelets in the bone ...
Asri Ragil Kemuning +4 more
doaj +1 more source
Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino +4 more
doaj +1 more source
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
BACKGROUND Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the ...
P. García-Pavía +13 more
semanticscholar +1 more source
Amyloidogenicity assessment of transthyretin gene variants
Objective Hereditary transthyretin‐mediated amyloidosis is a treatable condition caused by amyloidogenic variants in the transthyretin‐gene resulting in severe peripheral neuropathy or cardiomyopathy.
Nicolai B. Grether +11 more
doaj +1 more source
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy ...
Teresa Coelho +55 more
semanticscholar +1 more source
Background The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy.
D. Adams +15 more
semanticscholar +1 more source
Transthyretin amyloidosis (ATTR) is a progressive and systemic disease caused by the misfolding and amyloid aggregation of transthyretin (TTR). Stabilizing the TTR tetramers and disrupting the formed TTR aggregation are treated as a promising strategy for the treatment of ATTR.
Huizhen Zou, Shuangyan Zhou
openaire +2 more sources
Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study [PDF]
Background Hereditary Transthyretin Amyloidosis Polyneuropathy is a rare life-threatening neurologic disease that imposes considerable mortality and it is associated with progressive related disabilities.
Coelho, Teresa +5 more
core +2 more sources

